The latest approval is based on data from the Phase II DESTINY-Lung02 trial of Enhertu for treating unresectable advanced or recurrent non-small cell lung cancer. Credit: Africa Studio / Shutterstock.com.

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) to treat unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with HER2 (ERBB2) mutations in adults.

The treatment is indicated for use in patients who have advanced following treatment with chemotherapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The latest development is based on data from the international Phase II DESTINY-Lung02 clinical trial that is assessing the safety and efficacy of two doses of Enhertu.

Pre-specified interim assessment data from the trial showed that Enhertu offered a 53.8% objective response rate based on the blinded independent central review.

The regulatory agency previously granted an orphan drug designation for the therapy to treat this type of tumour, facilitating a priority review of the company’s application.

See Also:

Enhertu’s safety profile in DESTINY-Lung02 was in line with prior studies with no new safety concerns detected.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An antibody-drug conjugate directed at HER2, Enhertu is approved for four indications in the region.

Daiichi Sankyo Japan research and development division executive officer and head Wataru Takasaki stated: “HER2 mutant non-small cell lung cancer is a rare but serious disease and now patients and physicians in Japan have the potential to benefit from the first HER2 directed treatment option approved specifically for this type of lung cancer.

“This is the fourth indication secured for Enhertu in Japan in just over three years and the second approval this year alone, underscoring the benefit of this medicine across a range of HER2 targetable cancers.”

The US Food and Drug Administration recently approved Enhertu to treat unresectable or metastatic non-small cell lung cancer.